Ratings Trulieve Cannabis Corp.

Equities

TRUL

CA89788C1041

Market Closed - Canadian Securities Exchange Other stock markets 15:59:59 2024-04-30 EDT			5-day change	1st Jan Change
19.75 ^CAD	-.--%		+35.93%	+188.32%

04-30	Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug	RE
04-22	Trulieve Cannabis Brief: Opening Medical Cannabis Dispensary in North Palm Beach, Florida	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company has insufficient levels of profitability.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TRULIEVE CANNABIS CORP.	+188.32%	2.69B		C
CURALEAF HOLDINGS, INC.	+56.08%	4.64B		C-
GOODNESS GROWTH HOLDINGS, INC.	+144.44%	80.19M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes